MX2010006215A - Derivados de piperazina y su uso como moduladores del receptor de leptina. - Google Patents

Derivados de piperazina y su uso como moduladores del receptor de leptina.

Info

Publication number
MX2010006215A
MX2010006215A MX2010006215A MX2010006215A MX2010006215A MX 2010006215 A MX2010006215 A MX 2010006215A MX 2010006215 A MX2010006215 A MX 2010006215A MX 2010006215 A MX2010006215 A MX 2010006215A MX 2010006215 A MX2010006215 A MX 2010006215A
Authority
MX
Mexico
Prior art keywords
compounds
new compounds
preparation
dyslipidemias
diabetes
Prior art date
Application number
MX2010006215A
Other languages
English (en)
Inventor
Iain Simpson
Joseph W Boyd
Giles A Brown
Michael Higginbottom
Viet-Anh Anne-Nee-Nguyen Horgan
Jacqueline Ouzman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2010006215A publication Critical patent/MX2010006215A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención se refiere a compuestos novedosos de la formula (I), a composiciones farmacéuticas que comprenden estos compuestos, a procesos para su preparación y el uso de estos compuestos como miméticas de modulador de receptor de leptina en la preparación de medicamentos para condiciones relacionadas con aumento de peso, diabetes de tipo 2 y dislipidemias.
MX2010006215A 2007-12-05 2008-12-05 Derivados de piperazina y su uso como moduladores del receptor de leptina. MX2010006215A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0702697 2007-12-05
US2293308P 2008-01-23 2008-01-23
PCT/EP2008/066899 WO2009071668A2 (en) 2007-12-05 2008-12-05 Piperazine derivatives and their use as leptin receptor modulators

Publications (1)

Publication Number Publication Date
MX2010006215A true MX2010006215A (es) 2010-08-17

Family

ID=40673212

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006215A MX2010006215A (es) 2007-12-05 2008-12-05 Derivados de piperazina y su uso como moduladores del receptor de leptina.

Country Status (12)

Country Link
US (1) US8093248B2 (es)
EP (1) EP2234992B1 (es)
JP (1) JP2011506295A (es)
KR (1) KR20100096222A (es)
CN (1) CN102015668A (es)
AT (1) ATE546441T1 (es)
AU (1) AU2008333183A1 (es)
BR (1) BRPI0820950A2 (es)
CA (1) CA2707248A1 (es)
MX (1) MX2010006215A (es)
RU (1) RU2010126842A (es)
WO (1) WO2009071668A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE546441T1 (de) 2007-12-05 2012-03-15 Astrazeneca Ab Piperazinderivate und ihre verwendung als modulatoren des leptinrezeptors
JP2011506298A (ja) * 2007-12-05 2011-03-03 アストラゼネカ アクチボラグ 新規化合物ｉｖ
MX2010006259A (es) 2007-12-05 2010-08-23 Astrazeneca Ab Piperazinas como agentes antiobesidad.
CN102166214B (zh) * 2011-03-02 2012-12-12 华中科技大学同济医学院附属同济医院 氨基噻唑类MyD88特异性抑制剂在医学上的用途
US9034874B2 (en) * 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
CN105622528B (zh) * 2016-02-01 2017-12-15 新乡医学院第一附属医院 一种治疗肺动脉高压的化合物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3420193A1 (de) 1984-05-30 1985-12-05 Boehringer Ingelheim KG, 6507 Ingelheim Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel
NZ332879A (en) 1996-06-06 2000-09-29 Smithkline Beecham Plc Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes
TW434220B (en) 1998-02-02 2001-05-16 Shiseido Co Ltd 1,2-di-substituted piperidine derivative, a hair growth agent, and an agent for external use to the skin
JP2001131149A (ja) 1999-11-08 2001-05-15 Sumitomo Pharmaceut Co Ltd 選択的セロトニン再取り込み阻害剤
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
CZ20031194A3 (cs) 2000-09-29 2003-08-13 Glaxo Group Limited Deriváty močoviny
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
DE60234453D1 (de) 2001-07-02 2009-12-31 High Point Pharmaceuticals Llc Substituierte piperazin- und diazepanderivate zur verwendung als histamin h3 rezeptormodulatoren
ES2197003B1 (es) 2002-04-08 2005-03-16 J. URIACH & CIA S.A. Nuevos compuestos antagonistas de integrinas alfa.
JP2006509815A (ja) 2002-12-13 2006-03-23 ファイザー・プロダクツ・インク 新規なリン含有誘導体
WO2005016902A1 (en) 2003-06-20 2005-02-24 Arena Pharmaceuticals, Inc. N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
CN102633730A (zh) 2004-12-03 2012-08-15 先灵公司 作为cb1拮抗剂的取代哌嗪
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090203676A1 (en) 2005-06-30 2009-08-13 Oscar Barba G-protein Coupled Receptor Agonists
WO2007025613A2 (en) 2005-07-15 2007-03-08 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
EP1787679A1 (en) 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
EP1909797A4 (en) 2005-08-02 2013-02-27 Neurogen Corp DIPIPERAZINYL KETONE AND RELATED ANALOG
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US20090181976A1 (en) 2006-02-28 2009-07-16 Buschmann Helmut H Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome
WO2008025799A1 (en) 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyridazine compounds for treating gpr119 related disorders
US20090005375A1 (en) 2007-03-30 2009-01-01 Edcon Chang Acetyl coenzyme a carboxylase inhibitors
TW200902007A (en) 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
JP2011506298A (ja) 2007-12-05 2011-03-03 アストラゼネカ アクチボラグ 新規化合物ｉｖ
WO2009071677A1 (en) 2007-12-05 2009-06-11 Biovitrum Ab (Publ) New compounds iii
ATE546441T1 (de) 2007-12-05 2012-03-15 Astrazeneca Ab Piperazinderivate und ihre verwendung als modulatoren des leptinrezeptors
MX2010006259A (es) 2007-12-05 2010-08-23 Astrazeneca Ab Piperazinas como agentes antiobesidad.
CN102245183A (zh) 2008-06-04 2011-11-16 阿斯利康(瑞典)有限公司 新化合物v
CN102159542A (zh) 2008-06-04 2011-08-17 阿斯利康(瑞典)有限公司 新化合物vii
MX2010013359A (es) 2008-06-04 2011-04-07 Astrazeneca Ab Nuevos derivados de piridina como mimeticos moduladores del receptor de leptina.
CN102159545A (zh) 2008-06-04 2011-08-17 阿斯利康(瑞典)有限公司 小分子瘦蛋白受体调节剂

Also Published As

Publication number Publication date
ATE546441T1 (de) 2012-03-15
CA2707248A1 (en) 2009-06-11
KR20100096222A (ko) 2010-09-01
US20090281087A1 (en) 2009-11-12
WO2009071668A2 (en) 2009-06-11
RU2010126842A (ru) 2012-01-10
BRPI0820950A2 (pt) 2015-07-07
US8093248B2 (en) 2012-01-10
WO2009071668A3 (en) 2009-08-20
EP2234992A2 (en) 2010-10-06
JP2011506295A (ja) 2011-03-03
CN102015668A (zh) 2011-04-13
EP2234992B1 (en) 2012-02-22
AU2008333183A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
MY149622A (en) Pyrazoles as 11-beta-hsd-1
MY155695A (en) Quinoxalinedione derivatives
MA32383B1 (fr) DÉRIVÉS D'INDAZOLES à SUBSTITUTIONS PHÉNYLE ET BENZODIOXYNYLE
MX2009010047A (es) Compuestos quimicos.
MX2010010508A (es) Composiciones de absorcion de sebo.
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
MX2009010045A (es) Compuestos quimicos.
MY146969A (en) Dpp iv inhibitor formulations
HK1154777A1 (en) Lipoprotein lipase-activating compositions comprising benzene derivatives
JO2770B1 (en) Organic compounds
TW200745122A (en) New compounds I
MX2010006259A (es) Piperazinas como agentes antiobesidad.
TW200738627A (en) Trialkylsilyl-indoles
MX2010006215A (es) Derivados de piperazina y su uso como moduladores del receptor de leptina.
MX2010001243A (es) Composicion anti-inflamatoria.
MX2010006216A (es) Nuevos compuestos iii.
CA2725949A1 (en) New pyridine derivatives as leptin receptor modulator mimetics
TW200745133A (en) New compounds II
TW200800993A (en) Organic compounds
MX2010006220A (es) Derivados de morfolina como agentes antiobesidad.
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
WO2009034432A8 (en) Novel compounds active as muscarinic receptor antagonists
GB0615105D0 (en) Novel compounds
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
GB0620619D0 (en) Novel compounds